norton nancy1

Nancy Norton is a prominent advocate for the study and treatment of functional gastrointestinal and motility disorders.

Since 1991, she has worked to present the perspective of patients and their needs to the health care community.

On behalf of IFFGD, she organized the biennial International Symposium on Functional Gastrointestinal Disorders, a forum for international experts. Ms. Norton has provided testimony to the U.S. Senate and House of Representatives Appropriation Subcommittees on Labor, Health and Human Services, and Education.

Professional Societies

Ms. Norton serves in several prominent professional societies, providing a voice on behalf of patients. Her roles have included:


Ms. Norton has worked on many research studies as well as contributions to books and reviews aimed at improving health and daily living for people affected by functional GI and motility disorders.

  • Kurlander JE, Chey WD, Morris CB, Hu YJB, Padival RK, Bangdiwala SI, Norton NJ, Norton WF, Drossman DA. Development and validation of the Patient-Physician Relationship Scale among patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017 Oct;29(10):1-8.
  • Yu D, Ramsey FV, Norton WF, Norton N, Schneck S, Gaetano T, Parkman HP. The burdens, concerns, and quality of life of patients with gastroparesis. Dig Dis Sci. 2017 Jan 21. doi: 10.1007/s10620-017-4456-7.
  • Norton NJ. Functional bowel disorders: a patient’s perspective. Am J Gastroenterol. 2016 Apr;111(4):451-1.
  • Dorn SD, Morris CB, Schneck SE, Hopper TM, Hu YJ, Kelapure R, Weinland SR, Norton WF, Norton NJ, Drossman DA. Development and validation of the irritable bowel syndrome satisfaction with care scale. Clin Gastroenterol Hepatol. 2011 Dec;9(12):1065-71.e1-2. Epub 2011 Aug 18.
  • Parkman HP, Camilleri M, Farrugia G, McCallum RW, Bharucha AE, Mayer EA, Tack JF, Spiller R, Horowitz M, Vinik AI, Galligan JJ, Pasricha PJ, Kuo B, Szarka LA, Marciani L, Jones K, Parrish CR, Sandroni P, Abell T, Ordog T, Hasler W, Koch KL, Sanders K, Norton NJ, Hamilton F. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil. 2010 Feb;22(2):113-33. Epub 2009 Dec 9. Review.
  • Halpert A, Dalton CB, Palsson O, Morris C, Hu Y, Bangdiwala S, Hankins J, Norton N, Drossman DA. Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: a national survey. Dig Dis Sci. 2010 Feb;55(2):375-83. Epub 2009 Jun 10.
  • Drossman D.A., Morris C.B., Schneck S., Hu Y.J.B., Norton N.J., Norton W.F., Weinland S., Dalton C., Leserman J., Bangdiwala S.I. International survey of patients with IBS: Symptom features and their severity, health status,treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol.2009 Jul;43(6):541-50.
  • Drossman D.A., Chang L., Schneck S., Blackman C., Norton W.F., Norton N.J. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009 Apr 1.
  • Norton N.J.. Foreword: A Patient’s View. In Thompson WG. Understanding the Irritable Gut: The Functional Gastrointestinal Disorders. McLean VA, Degnon Associates, 2008.
  • Chang L., Toner B.B., Fukudo S., Guthrie E., Locke G.R., Norton N.J., Sperber A.D., Gender, Age, Society, Culture, and the Patient's Perspective in the Functional Gastrointestinal Disorders, in Drossman DA (sr ed): Rome III: The Functional Gastrointestinal Disorders, Degnon Associates, Inc. 2006, Ch. 5, pp. 232-237. 
  • Chang L., Toner B.B., Fukudo S., Guthrie E., Locke G.R., Norton N.J., Sperber A.D. Gender, Age, Society, Culture, and the Patient's Perspective in the Functional Gastrointestinal Disorders. Gastroenterology. 2006 May; 130(5):1435-1446.
  • Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, Norton NJ, Whorwell P. Severity in irritable bowel syndrome: a Rome Foundation working team report. Am J Gastroenterol. 2011 Jul 12. doi: 10.1038/ajg.2011.201. [Epub]
  • Norton, N.J., The Perspective of the Patient. Gastroenterology 2004 Jan;126(1 Suppl 1):S175-9.
  • Whitehead W.E., Wald A., Norton N.J. Priorities for treatment research from different professional perspectives: Gastroenterology. 2004 Jan;126(1 Suppl 1):S180-5.
  • Whitehead W.E., Norton N.J., Wald A. Introduction. Advancing the treatment of fecal and urinary incontinence through research. Gastroenterology. 2004 Jan;126(1 Suppl 1):S1-2.
  • Cohen S, Bacon BR, Berlin JA, Fleischer D, Hecht GA, Loehrer PJ Sr, McNair AE Jr, Mulholland M, Norton NJ, Rabeneck L, Ransohoff DF, Sonnenberg A, Vannier MW. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc. 2002 Dec;56(6):803-9.
  • Whitehead, W., Wald, A., Norton, N., Treatment Options for Fecal Incontinence: A Consensus Conference Report, Diseases of the Colon and Rectum. Vol. 44, No. 1, 131-142, 2001.
  • Norton, N.J., The Patient Experience, Functional GI Disorders, Irritable Bowel Syndrome. Part 1, Nosology, Epidemiology, and Pathophysiology. American Digestive Health Foundation, 1999.
  • Norton, N.J., Patient Advocacy and Self-help Groups, in Olden. K.W. (ed): Handbook of Functional Gastrointestinal Disorders, Marcel Dekkar, Inc. 1996, Ch. 14, pp. 329-336.
  • Nelson, R., Norton, N., Cautley, E., Furner, S., Community-Based Prevalence of Anal Incontinence, Journal of the American Medical Association. Vol. 274, No. 7, 559-561, 1995.
  • Norton, N.J., Epilogue, in Schuster, M.M. and Wehmueller, J., Keeping Control – Understanding and Overcoming Fecal Incontinence, Johns Hopkins University Press, 1994, pg. 137-146.
Nancy J. Norton, IFFGD Founder
Ceciel T. Rooker, IFFGD President
Advisory Board
Officers and Board of Directors
Our Mission
Awareness Activities & Accomplishments
Public Education & Awareness
Professional Education & Awareness
Year in Review
Advocacy Activities
Legislative Successes
FGIMD Act (Functional Gastrointestinal and Motility Disorders Research Enhancement Act)
Congressional Testimony
FDA and Other Testimony
Written Comments to FDA December 30, 2019
Written Comments to FDA October 15, 2019
Written Comments to SSA September 23, 2019
Written comments to FDA April 30, 2019
Written Comments to SSA February 15, 2019
Written Comments to HHS February 5, 2019
Written Comments to DoD December 13, 2018
Written Comments to FDA October 18, 2018
Written Comments to FDA October 17, 2018
Written Presentation to FDA September 12, 2017
Written Comments to FDA June 29, 2015
Oral Comments to FDA May 11, 2015
Comments to FDA July 16th, 2014
Written Comments to Noridian October 24, 2013
Testimony to FDA October 25, 2012
Testimony to FDA September 12, 2012
Testimony to FDA December 13, 2011
Testimony to FDA December 2, 2010
Testimony to FDA April 23, 2002
Comments to FDA November 9, 2000
Testimony to FDA June 27, 2000
Testimony to FDA June 26, 2000
Capitol Hill Advocacy Day
National Institutes of Health (NIH)
IFFGD Research Awards
IFFGD Symposium reports
2013 Professional Symposium
10th Symposium Report
10th Symposium Audio Recordings
More from the 10th Symposium on FGIDs
2011 Professional Symposium
9th Symposium Report
2009 Professional Symposium
2007 Professional Symposium
7th Symposium Report
2005 Professional Symposium
6th Symposium Report
2003 Professional Symposium
5th Symposium Report
2002 Conference - Advancing the Treatment of Incontinence
Corporate Support
Our Research Funding Needs
IFFGD Standards for Collaboration
Industry Council
Code of Ethics
Contact Us
Media Contact
Ambassadors Program
2019 Ambassadors

Advocacy Effort

capital hill day s

Involvement in Shaping National Health Care Policy

IFFGD is a voice on Capital Hill working with the digestive health community.

Advocacy Activities, Legislative & Regulatory

Legislative Successes

Congressional Testimony